HKD24.75
2.48% today
Hong Kong, May 21, 05:45 am CET
ISIN
KYG970081173
Symbol
2269
Index
Sector
Industry

WuXi Biologics Stock price

HKD24.15
+3.65 17.80% 1M
+8.79 57.23% 6M
+6.59 37.53% YTD
+10.11 72.01% 1Y
-32.15 57.10% 3Y
-20.42 45.81% 5Y
+14.73 156.46% 10Y
Hong Kong, Closing price Tue, May 20 2025
+0.40 1.68%
ISIN
KYG970081173
Symbol
2269
Index
Sector
Industry

Key metrics

Market capitalization HKD98.09b
Enterprise Value HKD95.83b
P/E (TTM) P/E ratio 27.24
EV/FCF (TTM) EV/FCF 58.10
EV/Sales (TTM) EV/Sales 4.73
P/S ratio (TTM) P/S ratio 4.84
P/B ratio (TTM) P/B ratio 2.23
Revenue growth (TTM) Revenue growth 7.52%
Revenue (TTM) Revenue HKD20.25b
EBIT (operating result TTM) EBIT HKD4.97b
Free Cash Flow (TTM) Free Cash Flow HKD1.65b
EPS (TTM) EPS HKD0.86
P/E forward 22.76
P/S forward 4.33
EV/Sales forward 4.23
Show more

Is WuXi Biologics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

WuXi Biologics Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a WuXi Biologics forecast:

19x Buy
68%
9x Hold
32%

Analyst Opinions

28 Analysts have issued a WuXi Biologics forecast:

Buy
68%
Hold
32%

Financial data from WuXi Biologics

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
20,249 20,249
8% 8%
100%
- Direct Costs 11,953 11,953
6% 6%
59%
8,296 8,296
10% 10%
41%
- Selling and Administrative Expenses 693 693
13% 13%
3%
- Research and Development Expense 831 831
4% 4%
4%
6,771 6,771
15% 15%
33%
- Depreciation and Amortization 1,799 1,799
18% 18%
9%
EBIT (Operating Income) EBIT 4,972 4,972
14% 14%
25%
Net Profit 3,639 3,639
4% 4%
18%

In millions HKD.

Don't miss a Thing! We will send you all news about WuXi Biologics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.

Head office Cayman Islands
CEO Zhi Chen
Employees 12,575
Founded 2010
Website www.wuxibiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today